Efficacy and safety of adding mizoribine to standard treatment in patients with immunoglobulin A nephropathy: A randomized controlled trial

BACKGROUND: Mizoribine (MZR) is an immunosuppressive drug used in Japan for treating patients with lupus nephritis and nephrotic syndrome and has been also reportedly effective in patients with immunoglobulin A (IgA) nephropathy. However, to date, few randomized control studies of MZR are performed...

Descripción completa

Detalles Bibliográficos
Autores principales: Hirai, Keiji, Ookawara, Susumu, Kitano, Taisuke, Miyazawa, Haruhisa, Ito, Kiyonori, Ueda, Yuichirou, Kaku, Yoshio, Hoshino, Taro, Mori, Honami, Yoshida, Izumi, Kubota, Kenji, Yamaji, Yasuyoshi, Takeda, Tetsuro, Nakamura, Yoshikazu, Tabei, Kaoru, Morishita, Yoshiyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society of Nephrology 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5491162/
https://www.ncbi.nlm.nih.gov/pubmed/28680823
http://dx.doi.org/10.23876/j.krcp.2017.36.2.159

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5491162/
https://www.ncbi.nlm.nih.gov/pubmed/28680823
http://dx.doi.org/10.23876/j.krcp.2017.36.2.159

Ejemplares similares